ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Biochemistry Research International is a prominent and dynamic journal published by Hindawi Ltd, dedicated to advancing knowledge in the field of biochemistry. With its Open Access model established since 2010, the journal provides unrestricted access to high-quality research, thereby fostering global communication among researchers and professionals. Operating out of the United States, Biochemistry Research International serves as a vital platform for disseminating cutting-edge findings in biochemistry and molecular biology, holding a respectable Q2 ranking in its category as of 2023. The journal's scope encompasses a wide array of topics including but not limited to biochemical processes, genetic engineering, and molecular interactions, making it an essential resource for students and seasoned researchers alike. With an impact factor reflective of its significance in the academic community, Biochemistry Research International continues to play an integral role in shaping the future of biochemistry research.